

Radiolabeled Compounds for Diagnosis and Treatment of Cancer II

Guest Editor:

Dr. Krishan Kumar

Vaccine Translational Research
Branch/VRP/DAIDS, National
Institute of Allergy and Infectious
Diseases (NIH), 5601 Fishers Lane,
Room 9B56, Rockville, MD 20892,
USA

Deadline for manuscript
submissions:

closed (31 October 2022)


Message from the Guest Editor

Significant advances in the design and evaluation of novel radiopharmaceuticals in preclinical and clinical environments have allowed for wider adoption of imaging technologies, such as SPECT and PET, and treatment of various cancers. Numerous radiopharmaceuticals have become commercially available for a range of applications, and more are undergoing development and the regulatory approval process. These radiopharmaceuticals are critical to the diagnosis and staging of diseases, as well as the selection of patients for various therapies and the monitoring of their outcomes.

The editorial team of *Molecules* is developing a Special Issue titled “Radiolabeled Compounds for Diagnosis and Treatment of Cancer”, which will focus on all aspects of design, characterization, evaluation and development of novel radiolabeled compounds for the diagnosis and treatment of cancer, as well as the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds.

Submissions—both original research papers and reviews—related to the areas mentioned above are desired.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](#)